RBF Capital LLC Sells 68,276 Shares of Keros Therapeutics, Inc. $KROS

RBF Capital LLC trimmed its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 45.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 81,724 shares of the company’s stock after selling 68,276 shares during the quarter. RBF Capital LLC’s holdings in Keros Therapeutics were worth $1,664,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Financial Management Professionals Inc. purchased a new position in Keros Therapeutics during the fourth quarter worth $29,000. Tower Research Capital LLC TRC boosted its stake in Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after buying an additional 1,888 shares during the period. New York State Common Retirement Fund boosted its stake in Keros Therapeutics by 264.1% during the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after buying an additional 7,700 shares during the period. Sherbrooke Park Advisers LLC purchased a new position in Keros Therapeutics during the third quarter worth $176,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Keros Therapeutics by 8.6% during the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after buying an additional 988 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the stock. Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Weiss Ratings lowered shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Finally, Wall Street Zen lowered shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $20.40.

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $10.03 on Wednesday. Keros Therapeutics, Inc. has a 1-year low of $9.69 and a 1-year high of $22.55. The company has a 50-day moving average of $11.16 and a 200 day moving average of $14.80. The firm has a market cap of $198.49 million, a PE ratio of -3.33 and a beta of 0.94.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The business had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. Sell-side analysts anticipate that Keros Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Insider Buying and Selling

In other Keros Therapeutics news, Director Alpna Seth sold 2,625 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the transaction, the director directly owned 9,767 shares in the company, valued at approximately $104,702.24. The trade was a 21.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the transaction, the director owned 10,958 shares of the company’s stock, valued at $117,579.34. This represents a 19.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,425 shares of company stock valued at $89,995 over the last three months. 22.90% of the stock is owned by company insiders.

Keros Therapeutics Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.